News
📈 Stocks
Neurocrine Biosciences Posts 39% Revenue Growth Amid KINECT-PRO Clinical Wins
(just now)
Neurocrine Biosciences balances robust 39% revenue growth and positive clinical data for INGREZZA against a tightened balance sheet following its $2.9 billion…